Overview and Rationale for Targeting TRK Fusions in Solid Tumors

In this downloadable slideset, George D. Demetri, MD, provides an overview on the biology of NTRK fusions in patients with cancer and the rationale for using TRK inhibitors in clinical practice.
George D. Demetri, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 4.81 MB
Released: June 4, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Drs Matthew Gubens and Craig Mackinnon discuss biomarker testing and treatment strategies for patients with NSCLC in a focused, expert-authored module from Clinical Care Options (CCO)

Matthew Gubens, MD, MS person default Craig Mackinnon, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: July 6, 2022 Expired: July 5, 2023

Downloadable slides on biomarker testing and treatment strategies for patients with NSCLC, from Clinical Care Options (CCO)

Matthew Gubens, MD, MS person default Craig Mackinnon, MD, PhD Released: July 6, 2022

Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 30, 2022

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings